SCHEMBL523763

SCHEMBL523763

C[C@H](Nc1ncc2c(n1)N(C1CCCC1)CC(C)(C)C(=O)N2C)c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 3/20 0.44
PDE1C Q14123 2/20 0.44
PLK1 P53350 10/20 0.43
PDE9A O76083 5/20 0.42
PDE1B Q01064 3/20 0.42
PDE5A O76074 2/20 0.42
PDE2A O00408 1/20 0.42
PDE8A O60658 1/20 0.42
PDE4D Q08499 1/20 0.42
PDE7A Q13946 1/20 0.42
PDE10A Q9Y233 1/20 0.42
BRD4 O60885 1/20 0.40
BRDT Q58F21 1/20 0.40
TTK P33981 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL523764 1.00 IDH1 (0.44) IDH1PDE1CPLK1PDE9APDE1B
SCHEMBL523872 0.92 PLK1 (0.43) IDH1PLK1BRD4BRDTTTK
SCHEMBL523542 0.92 PLK1 (0.43) IDH1PLK1BRD4BRDTTTK
SCHEMBL522743 0.91 PLK1 (0.45) IDH1PLK1BRD4BRDTTTK
SCHEMBL522608 0.91 PLK1 (0.43) IDH1PLK1BRD4BRDTTTK
SCHEMBL522540 0.91 PLK1 (0.43) IDH1PLK1BRD4BRDTTTK
SCHEMBL524145 0.91 PLK1 (0.45) IDH1PLK1BRD4BRDTTTK
SCHEMBL522384 0.91 IDH1 (0.45) IDH1PLK1PDE9ABRD4BRDT
SCHEMBL522605 0.91 IDH1 (0.45) IDH1PLK1PDE9ABRD4BRDT
SCHEMBL13551772 0.90 PLK1 (0.42) IDH1PLK1BRD4BRDTTTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120322793-A1 PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-20 US claimed
US-8278297-B2 Protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-02 US claimed
US-20120028966-A1 PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US claimed
EP-2356122-A1 PROTEIN KINASE INHIBITORS Vertex Pharmceuticals Incorporated (US) 2011-08-17 EP claimed
WO-2010008454-A1 PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-01-21 WO claimed
EP-2356122-B1 PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2019-03-20 EP disclosed
US-8618106-B2 Protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-12-31 US disclosed
US-20120322793-A1 PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-20 US disclosed
US-8278297-B2 Protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-02 US disclosed
US-20120028966-A1 PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed
WO-2011036566-A1 METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322793-A1 PROTEIN KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 IDH1 1107/4885PDE1C 768/4885PLK1 86/4885
US-20120028966-A1 PROTEIN KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 IDH1 1107/4885PDE1C 768/4885PLK1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.